Background
==========

Chondrosarcomas represent a heterogeneous group of malignant neoplasms with diverse histopathological features and are characterized by producing cartilaginous matrix \[[@b1-medscimonit-25-8952]\]. As the second most common primary malignancy of bone, the annual incidence of chondrosarcoma in the United States is about 1 in 200 000 \[[@b2-medscimonit-25-8952]\]. The prognosis of chondrosarcoma is tightly associated with the histological grade \[[@b2-medscimonit-25-8952]--[@b4-medscimonit-25-8952]\]. The low-grade chondrosarcoma with abundant cartilage matrix and poor cellularity, is prone to be localized and shows a good prognosis after surgical resection \[[@b5-medscimonit-25-8952]\]. However, high-grade tumors show little cartilage matrix and high cellularity, and easily metastasize, leading to dismal prognoses \[[@b1-medscimonit-25-8952],[@b6-medscimonit-25-8952]\].

Previous studies have analyzed the prognostic factors and treatment regimens for chondrosarcoma. Bindiganavile et al. demonstrated that histological grade and tumor location could predict the outcome of chondrosarcoma, and the patients with high-grade and axial-location tumors suffered the worst prognosis \[[@b7-medscimonit-25-8952]\]. Arshi et al. elucidated that age at diagnosis, extent of tumor, surgical resection were independent survival determinants for spinal chondrosarcoma \[[@b8-medscimonit-25-8952]\]. However, almost all of these studies focused on the entire entity of chondrosarcoma rather than on different histological grades, and to our knowledge, the prognostic study exclusive to high-grade chondrosarcoma has not been reported. Given the significant diversity between the low-and high-grade chondrosarcoma, whether these prognostic factors and treatment strategies can also be applied to high-grade tumors is largely unknown. In addition, due to the few dividing cells, rich cartilage matrix, and poor vascularization, chondrosarcoma is resistant to radiotherapy \[[@b9-medscimonit-25-8952]--[@b11-medscimonit-25-8952]\]. Although some studies have demonstrated that adjuvant radiotherapy could be beneficial for local control of chondrosarcoma, it failed to achieve better overall survival (OS) or cancer-specific survival (CSS) \[[@b12-medscimonit-25-8952]--[@b16-medscimonit-25-8952]\]. However, whether high-grade chondrosarcoma, which typically shows higher cellularity and less matrix \[[@b1-medscimonit-25-8952]\], is sensitive to radiotherapy is also unclear. Therefore, it is meaningful to address the prognostic indicators and effective treatment of high-grade chondrosarcoma, which may be beneficial to optimize the treatment regimen and improve patient survival.

The Surveillance, Epidemiology, and End Results (SEER) cancer registry database is maintained by National Cancer Institute, which routinely records the cancer incidence and survival data from 18 population-based cancer registries. The database doesn't include the specific chemotherapy data, and the specific information of radiotherapy and surgery, such as the doses of radiotherapy and the margins of surgical resection. In the SEER cancer registry database, the histological grade includes 4 categories: well differentiated (grade 1), moderately differentiated (grade 2), poorly differentiated (grade 3), and undifferentiated (grade 4). As reported in a previous study \[[@b17-medscimonit-25-8952]\], we categorized poorly differentiated and undifferentiated as high-grade. The method to classify the grade is an assessment of the similarity between the tumor cells and the normal cells of the original organ. The grade 3 tumor (poorly differentiated) has some, or little similarity to the original organ, while the grade 4 (undifferentiated) tumor has no similarity to the original organ \[[@b18-medscimonit-25-8952]\].

The following questions were addressed in this study: 1) what is the 5 year-OS and CSS for patients with high-grade chondrosarcoma; 2) what are the prognostic factors exclusive for high-grade chondrosarcoma; 3) whether the application of adjuvant radiotherapy can improve the survival of patients with high-grade tumors; and 4) whether the prognostic factors of poorly differentiated and undifferentiated tumors are different due to the biological and clinical differences.

Material and Methods
====================

Patients selection
------------------

Due to public access and no unique identification for patients in the SEER database, ethical review was waived after the discussion by the Ethics Committee of Xi'an Jiaotong University (Xi'an, China). The SEER\*Stat software (version 8.3.4) was employed to extract the chondrosarcoma cases diagnosed between 1973 and 2014. The following histologic ICD-O-3 codes (International Classification of Diseases for Oncology, Third Edition) were included: code 9220 (chondrosarcoma not otherwise specified), code 9221 (juxtacortical chondrosarcoma), code 9231 (myxoid chondrosarcoma), code 9240 (mesenchymal chondrosarcoma), code 9242 (clear cell chondrosarcoma) and code 9243 (dedifferentiated chondrosarcoma). According to the definition of ICD-0-3: chondrosarcoma, NOS: the most common subtype of chondrosarcoma, which comprises about 75% of the tumors, and is characterized by the chondromyxoid matrix material \[[@b19-medscimonit-25-8952]\]; myxoid chondrosarcoma: it is characterized by the formation of myxoid stroma, and includes extraskeletal myxoid chondrosarcoma and the myxoid tumor of skull base \[[@b20-medscimonit-25-8952]\]; mesenchymal chondrosarcoma: a rare subtype of chondrosarcoma, which is characterized by undifferentiated small round cells in addition to the well differentiated hyaline cartilage \[[@b21-medscimonit-25-8952]\]; clear cell chondrosarcoma: a rare variant of chondrosarcoma, which is histologically characterized by the presence of bland clear cells \[[@b22-medscimonit-25-8952]\]; dedifferentiated chondrosarcoma: an aggressive subtype of chondrosarcoma, which contains 2 components, a low-grade cartilage sarcoma and a high-grade tumor without cartilage \[[@b23-medscimonit-25-8952]\]. The classification of these cases was reviewed and confirmed by one senior pathologist in our hospital.

The following criteria were applied to exclude some cases: 1) chondrosarcoma was not the primary tumor; 2) the tumor was diagnosed without histopathology confirmed; 3) the survival time was not clear; 4) the histological grade was well- or moderately-differentiated.

Study variables
---------------

Demographic variables, such as age, race, sex, marital status and socioeconomic status (SES), was analyzed in this study. Age was categorized as: \<60 years old and ≥60 years old. Race was recoded as white, black and other in the SEER database. Marital status was divided into 4 categories: married, divorced, single, and widowed. Socioeconomic status was created by standard 2000 US Census SES variables as previous studies \[[@b24-medscimonit-25-8952],[@b25-medscimonit-25-8952]\] and further categorized as low-SES and high-SES. Tumor-related variables, such as histological grade, tumor location, tumor size, SEER stage, and treatment options, were extracted from the database. The histological grade included 2 categories: poorly differentiated (grade 3) and undifferentiated (grade 4), according to the SEER database. To simplify the analysis, the histo-type was divided into: chondrosarcoma not otherwise specified, myxoid chondrosarcoma, mesenchymal chondrosarcoma, dedifferentiated chondrosarcoma, and other (including juxtacortical chondrosarcoma and clear cell chondrosarcoma). Tumor location was classified as axial (including pelvic bones, sacrum, coccyx, ribs, sternum, and vertebral columns), extremities (including bones of the upper and lower extremities) and other group (including bones of skull, mandible, and other atypical locations) as previous study \[[@b24-medscimonit-25-8952]\]. As coded in the SEER program, the SEER stage was divided into localized, regional, distant, and unstaged. Tumor size was categorized as: ≤8 cm, \>8 cm, and unknown. With regards to surgery and radiotherapy, both were divided into performed and not performed. For the treatment regimen, we included 4 groups: radiotherapy combined surgery, surgery only, radiotherapy only, and no treatment.

Statistical analysis
--------------------

In this study, OS and chondrosarcoma CSS were the primary outcomes. As described in the SEER database, the deaths caused by chondrosarcoma were considered as events for CSS, and the deaths from any cause were considered as events for OS. Descriptive analysis was carried out to assess the distribution of demographic and tumor-related variables. The Kaplan-Meier method was used to estimate the 5-year OS and CSS. The log-rank test was performed for univariate analysis, and the Cox regression model was conducted for multivariate analysis. The aforementioned statistical analyses were performed using SPSS statistics software, version 20 (IBM, SPSS, Inc., Chicago, IL, USA). All *P* values were 2-sided, and*P*\<0.05 indicated the significant difference.

Results
=======

Baseline patient characteristics
--------------------------------

A total of 743 patients with high-grade chondrosarcoma were identified in this study, of which 430 cases were diagnosed as poorly differentiated tumors and 313 cases were classified as undifferentiated tumors. Of these cases with high-grade chondrosarcoma, the majority were found in younger age (57.2%, n=425), white race (87.1%, n=647) and male (57.1%, n=424). The most common SEER stage of high-grade chondrosarcoma was regional (45.1%, n=335), followed by localized (30.1%, n=224) and distant (20.1%, n=149). Most patients were married (58.4%, n=434), followed by single (24.1%, n=179) and divorced (9.0%, n=67). Most patients underwent surgical resection (88.0%, n = 654), while the minority received radiotherapy (28.5%, n=212). The most common treatment regimens were surgery only (64.8%, n=482) and adjuvant radiotherapy combined surgery (23.1%, n=172). Similar distributions of patient demographics and tumor characteristics were found in poorly differentiated tumors and undifferentiated tumors. The baseline characteristics of this study were shown in [Table 1](#t1-medscimonit-25-8952){ref-type="table"}.

Survival analysis for patients with high-grade chondrosarcoma
-------------------------------------------------------------

Kaplan-Meier curves ([Figure 1A, 1B](#f1-medscimonit-25-8952){ref-type="fig"}) showed that the 5-year OS and CSS for patients with high-grade chondrosarcoma were 45.7% and 50.8%, respectively. Adjuvant radiotherapy combined surgery didn't make a difference on the survival of patients compared with surgery-only group, and surgical resection could significantly improve the outcomes of patients compared with radiotherapy-only or non-treatment groups (OS *P*\<0.00, [Figure 1C](#f1-medscimonit-25-8952){ref-type="fig"}; CSS *P*\<0.001, [Figure 1D](#f1-medscimonit-25-8952){ref-type="fig"}). In addition, both the OS and CSS analysis demonstrated that undifferentiated pathological grade, dedifferentiated histo-type, distant SEER stage, larger tumor size, and widowhood were associated with dismal prognoses. The multivariate analysis identified that pathological grade, histo-type, SEER stage, tumor size, and surgical resection were independent predictors for both OS and CSS of high-grade chondrosarcoma, and widowhood was an independent predictor for chondrosarcoma OS. Patients with undifferentiated chondrosarcoma suffered a remarkably higher risk of overall mortality (Hazard ratio \[HR\] 1.40, 95% confidence interval \[CI\] 1.14--1.72, *P*=0.001) and cancer-specific mortality (HR 1.38, 95% CI 1.10--1.73, *P*=0.005). Similarly, patients without surgical resection also had a dramatical increase in the risk of overall mortality (HR 2.00, 95% CI 1.51--2.66, *P*\<0.001) and cancer-specific mortality (HR 2.06, 95% CI 1.53--2.78, *P*\<0.001). The details of log-rank test and Cox regression were shown in [Table 2](#t2-medscimonit-25-8952){ref-type="table"}.

Subgroup survival analysis for patients with poorly differentiated chondrosarcoma
---------------------------------------------------------------------------------

To further determine the therapeutic effects of surgical resection and radiotherapy on poorly differentiated chondrosarcoma, we performed the Kaplan-Meier curves and log-rank test to evaluate the OS and CSS. The Kaplan-Meier curves revealed that the 5-year OS and CSS for patients with poorly differentiated chondrosarcoma were 54.2% and 60.1%, respectively ([Figure 2A, 2B](#f2-medscimonit-25-8952){ref-type="fig"}). Adjuvant radiotherapy combined surgery didn't significantly improve the patient outcomes compared with surgery-only group, and surgical resection could dramatically improve the survival rate of patients (OS *P*\<0.001, [Figure 2C](#f2-medscimonit-25-8952){ref-type="fig"}; CSS *P*\<0.001, [Figure 2D](#f2-medscimonit-25-8952){ref-type="fig"}). Similar with the survival analysis of high-grade tumors, greater age, dedifferentiated histo-type, distant SEER stage, and larger tumor size were associated with dismal prognoses in both OS and CSS. Widowhood and low-SES were associated with poor outcomes in OS analysis. By multivariate analysis, histo-type, SEER stage, tumor size, and surgical resection were determined as independent prognostic factors for both OS and CSS of poorly differentiated chondrosarcoma. The mortality risk of patients without surgical resection was more than 2 times than that of patients receiving surgical resection in OS (HR 2.58, 95% CI 1.72--3.88, *P*\<0.001) and CSS analysis (HR 2.35, 95% CI 1.55--3.56,*P*\<0.001). The results of survival analysis were shown in [Table 3](#t3-medscimonit-25-8952){ref-type="table"}.

Subgroup survival analysis for patients with undifferentiated chondrosarcoma
----------------------------------------------------------------------------

We next evaluated the therapeutic effects of surgical resection and adjuvant radiotherapy on undifferentiated chondrosarcoma by log-rank test and Cox regression analysis. The results showed that the 5-year OS and CSS for patients with undifferentiated chondrosarcoma were 33.1% and 37.1%, respectively ([Figure 3A, 3B](#f3-medscimonit-25-8952){ref-type="fig"}). Similar with the results of high-grade chondrosarcoma and poorly differentiated chondrosarcoma, surgical resection remained the effective treatment option for patients with undifferentiated chondrosarcoma. Strikingly, adjuvant radiotherapy combined surgery could significantly improve the outcomes of patients with undifferentiated chondrosarcoma in both OS and CSS analysis (OS *P*\<0.001, [Figure 3C](#f3-medscimonit-25-8952){ref-type="fig"}; CSS *P*\<0.001, [Figure 3D](#f3-medscimonit-25-8952){ref-type="fig"}), which was in contrast with the results in high-grade chondrosarcoma and poorly differentiated. Besides, greater age, extremities location, dedifferentiated histo-type, distant SEER stage, larger tumor size, and widowhood were associated with dismal prognoses in both OS and CSS. The Cox regression analysis demonstrated that radiotherapy was an independent protective factor for patients with undifferentiated chondrosarcoma in both OS (HR 1.57, 95% CI 1.09--2.27,*P*=0.017) and CSS (HR 1.66, 95% CI 1.11--2.50, *P*=0.016). In addition, age at diagnosis, tumor location, histo-type, SEER stage, tumor size, marital status, and surgical resection were also identified as independent prognostic factors for both OS and CSS. The results of survival analysis were shown in [Table 4](#t4-medscimonit-25-8952){ref-type="table"}.

Subgroup survival analysis for patients with different histo-types of undifferentiated chondrosarcoma
-----------------------------------------------------------------------------------------------------

To explore which histo-type of undifferentiated chondrosarcoma was sensitive to the adjuvant radiotherapy, the log-rank test and Cox regression analysis were performed. The log-rank test of undifferentiated myoxid chondrosarcoma showed both the 5-year OS and CSS of patients with adjuvant radiotherapy were much higher than that of patients without radiotherapy, although the differences were not significant ([Figure 4A, 4B](#f4-medscimonit-25-8952){ref-type="fig"}). The univariate analysis of undifferentiated dedifferentiated chondrosarcoma demonstrated that the adjuvant radiotherapy could remarkably benefit the OS and CSS (OS P=0.015, [Figure 4C](#f4-medscimonit-25-8952){ref-type="fig"}; CSS P=0.007, [Figure 4D](#f4-medscimonit-25-8952){ref-type="fig"}), and the Cox regression analysis demonstrated that radiotherapy was an independent protective factor for patients in both OS (HR 2.64, 95% CI 1.17--5.95, P=0.019) and CSS (HR 3.56, 95% CI 1.39--9.15, P=0.008) analysis. While the survival analysis showed that the adjuvant radiotherapy did not benefit the survival of patients with undifferentiated chondrosarcoma (NOS) and mesenchymal chondrosarcoma. Together, these results determined that the adjuvant radiotherapy combined with surgery could benefit the patients with undifferentiated myxoid and dedifferentiated chondrosarcoma rather than those with undifferentiated chondrosarcoma (NOS) and mesenchymal chondrosarcoma. The results of survival analysis were shown in [Table 5](#t5-medscimonit-25-8952){ref-type="table"}.

Discussion
==========

Since most prognostic studies focus on the entire entity of chondrosarcoma \[[@b2-medscimonit-25-8952],[@b26-medscimonit-25-8952]--[@b28-medscimonit-25-8952]\], the prognostic factors and optimal treatment for high-grade chondrosarcoma remain poorly understood. Given the significant diversity between different histopathology grades and the dismal prognosis of high-grade chondrosarcomas, prognostic studies specifically for high-grade tumors are imperative. In this study, we demonstrated that age at diagnosis, pathological grade, histo-type, SEER stage, tumor size and surgical resection were independent prognostic factors in OS and CSS analysis for the entire high-grade tumor group. While radiotherapy was identified as a protective factor in both OS and CSS analysis of patients with undifferentiated (grade 4) dedifferentiated chondrosarcoma, and adjuvant radiotherapy combined with surgery could improve both the OS and CSS of patients with undifferentiated (grade 4) myxoid and dedifferentiated chondrosarcoma, which encourage the application of adjuvant radiotherapy for patients with undifferentiated chondrosarcoma.

With an 88.5% CSS at 5 years \[[@b24-medscimonit-25-8952]\], the low-grade chondrosarcoma is often considered as an indolent cancer. However, the survival of patients with high-grade chondrosarcoma, especially the undifferentiated chondrosarcoma was unfavorable. In this study, the 5-year OS and CSS for poorly-differentiated chondrosarcoma were 54.2% and 60.1%, respectively, and the OS and CSS for undifferentiated chondrosarcoma were 33.1% and 37.1%, respectively, emphasizing the clinical difference between the poorly-differentiated and undifferentiated tumor. In consistent with our survival data, Fiorenza et al. found that the 5-year OS rate of grade-2 chondrosarcoma was 53%, and the survival rate of grade-3 tumor was 38% \[[@b29-medscimonit-25-8952]\]. Similarly, the study by Giuffrida et al. reported a 37% 5-year disease-specific survival rate of high-grade chondrosarcoma \[[@b2-medscimonit-25-8952]\]. However, a single institutional study including 31 patients with high-grade chondrosarcoma revealed that the 5-year disease-specific survival was 82.5% \[[@b7-medscimonit-25-8952]\], which was much higher than our study and other studies. The reason for the huge gap may be attributed to the small sample size in this single institutional study.

It seems that almost all previous studies on chondrosarcoma elucidated that radiotherapy and chemotherapy are not beneficial to the patients' outcome, and the surgical resection is the only effective treatment for patients with chondrosarcoma \[[@b30-medscimonit-25-8952]--[@b32-medscimonit-25-8952]\]. In the present study, we also found that surgical resection could benefit the OS and CSS of patients with high-grade chondrosarcoma. However, our study firstly demonstrated that the adjuvant radiotherapy combined with surgery could benefit both OS and CSS of patients with undifferentiated myxoid and dedifferentiated chondrosarcoma compared with other treatment regimens. Similar to our findings, a large-scale SEER study by Koshy et al. analyzed 6960 cases of high-grade soft tissue sarcomas, which included 154 cases of osseous and chondromatous neoplasms, suggesting that the radiotherapy was associated with improved 3-year OS \[[@b33-medscimonit-25-8952]\]. Some studies have shown radiotherapy could benefit the local tumor control and reduce the recurrence rate, but these studies failed to show the advantage of radiotherapy on survival. Drilon et al. identified 73 cases of localized myxoid chondrosarcoma and found that the patients with adjuvant radiotherapy exhibited a lower incidence of distant metastasis \[[@b20-medscimonit-25-8952]\]. Kawaguchi et al. retrospectively reviewed 43 cases of mesenchymal chondrosarcoma, which has higher malignant biological behavior than other histo-types and enhanced the effect of adjuvant radiotherapy on local tumor control, but no benefit on OS and disease-free survival was identified \[[@b13-medscimonit-25-8952]\]. Similarly, a systematic review by Xu et al. revealed that adjuvant radiotherapy may reduce local recurrence of mesenchymal chondrosarcoma but cannot improve the OS \[[@b12-medscimonit-25-8952]\]. The study of Holliday et al. included 19 patients with spinal chordoma and chondrosarcoma, noting that early postoperative adjuvant radiotherapy may contribute to 2-year local control \[[@b14-medscimonit-25-8952]\]. Together, these findings encourage the application of adjuvant radiotherapy in the treatment of high-grade chondrosarcoma, especially the undifferentiated myxoid and dedifferentiated chondrosarcoma.

Previous studies on chondrosarcoma have shown that anatomical location, tumor size, and stage can predict patient outcomes \[[@b34-medscimonit-25-8952]--[@b37-medscimonit-25-8952]\]. Similar to these studies, we demonstrated that tumor size and tumor stage were independent prognostic factors for high-grade tumors in OS and CSS analyses. However, we failed to determine the anatomical location as an independent prognostic factor of high-grade chondrosarcoma, indicating the different nature of high-grade tumors. Additionally, the present study showed that older age was associated with a significant worse survival in high-grade chondrosarcoma group and other 2 subgroups. Consistent with our findings, Giuffrida et al. reported that an age larger than 50 years was associated with a significant worse OS \[[@b2-medscimonit-25-8952]\]. Our previous study also determined age as an independent prognostic factor in CSS analysis \[[@b24-medscimonit-25-8952]\]. Together, these results reinforced the role of age in the management of chondrosarcoma. With regard to the marital status, the present study determined that widowhood was an independent risk factor in the subgroup of undifferentiated chondrosarcoma but not in the subgroup of poorly differentiated chondrosarcoma, suggesting the spousal support \[[@b38-medscimonit-25-8952]\] and psychosocial factors \[[@b39-medscimonit-25-8952]--[@b41-medscimonit-25-8952]\] play more important roles in higher malignant tumors. The spousal support could increase the frequency of medical screening and the adherence to the treatment \[[@b38-medscimonit-25-8952],[@b42-medscimonit-25-8952]\]. Besides, the widowhood status poses psychosocial stress on the surviving companions. The study by van Grootheest et al. revealed that the widowed people exhibited a high level of depression for a long time \[[@b40-medscimonit-25-8952]\]. It is well known that the psychosocial disorders exert adverse effects on the immune and endocrine systems and contribute to the dismal survival \[[@b43-medscimonit-25-8952]\]. Therefore, the widowhood patients with undifferentiated chondrosarcoma need more psychiatric intervention to improve the patients' outcome.

The surgical margins play a critical role in the control of the tumor local recurrence. Stevenson et al. demonstrated that the surgical margins determined the local recurrence in all grades of chondrosarcoma \[[@b44-medscimonit-25-8952]\]. Besides, our study determined that the adjuvant radiotherapy could benefit the patients with undifferentiated chondrosarcoma, while the radiation doses are also important for the treatment regimen \[[@b45-medscimonit-25-8952]\]. Due to the inherent characteristics of the SEER database, this study couldn't analyze the impact of surgical margins and radiotherapy doses on patients' survival. Moreover, chemotherapy may benefit the outcomes of patients with mesenchymal and dedifferentiated chondrosarcoma, but not other subtypes such as the conventional chondrosarcoma \[[@b46-medscimonit-25-8952]\]. In our study, we didn't include the chemotherapy due to the lack of the specific data in the database, which may lead to incomplete analysis of the optimal treatment regimen for patients with chondrosarcoma. Finally, the 4-grade system in the SEER database is not commonly used for chondrosarcoma, thus the application of our results may be compromised. Although with these limitations, our study was the first large series to investigate the effect of adjuvant radiotherapy on high-grade chondrosarcoma, and has observed the survival benefit on patients with undifferentiated myxoid and dedifferentiated tumors, which may enhance the confidence of applying adjuvant radiotherapy on high-grade chondrosarcoma, and maximize the patients' outcome.

Conclusions
===========

Our study first demonstrated that radiotherapy was an independent protective factor in both OS and CSS for undifferentiated (grade 4) dedifferentiated chondrosarcoma, and adjuvant radiotherapy combined with surgery can improve both the OS and CSS of patients with undifferentiated (grade 4) myxoid and dedifferentiated chondrosarcoma. In addition, we determined that age at diagnosis, pathological grade, histo-type, SEER stage, tumor size, and surgical resection were independent prognostic factors in OS and CSS analysis for the entire high-grade tumor group. Our findings encourage the application of adjuvant radiotherapy for patients with high-grade chondrosarcoma, especially the undifferentiated myxoid and dedifferentiated chondrosarcoma.
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###### 

Baseline demographics and clinicopathological characteristics of patients with high-grade chondrosarcoma in the SEER database.

  -------------------------------------------------------------------------------------
  Characteristics            Total\        Poorly differentiated\   Undifferentiated\
                             N=743         N=430                    N=313
  -------------------------- ------------- ------------------------ -------------------
  Age (years) at diagnosis                                          

   \<60                      425 (57.2%)   262 (60.9%)              163 (52.1%)

   ≥60                       318 (42.8%)   168 (39.1%)              150 (47.9%)

  Race                                                              

   White                     647 (87.1%)   379 (88.1%)              268 (85.6%)

   Black                     51 (6.9%)     29 (6.7%)                22 (7.0%)

   Other                     45 (6.0%)     22 (5.2%)                23 (7.4%)

  Sex                                                               

   Male                      424 (57.1%)   252 (58.6%)              172 (55.0%)

   Female                    319 (42.9%)   178 (41.4%)              141 (45.0%)

  Tumor location                                                    

   Axial                     212 (28.5%)   135 (31.4%)              77 (24.6%)

   Extremities               326 (43.9%)   175 (40.7%)              151 (48.2%)

   Other                     205 (27.6%)   120 (27.9%)              85 (27.2%)

  Histo-type                                                        

   Chondrosarcoma, NOS       417 (56.1%)   283 (65.8%)              134 (42.8%)

   Myxoid                    87 (11.7%)    50 (11.6%)               37 (11.8%)

   Mesenchymal               72 (9.8%)     35 (8.2%)                37 (11.8%)

   Dedifferentiated          154 (20.7%)   52 (12.1%)               102 (32.5%)

   Other                     13 (1.7%)     10 (2.3%)                3 (1.1%)

  SEER stage                                                        

   Localized                 224 (30.1%)   138 (32.1%)              86 (27.5%)

   Regional                  335 (45.1%)   200 (46.5%)              135 (43.1%)

   Distant                   149 (20.1%)   66 (15.3%)               83 (26.5%)

   Unstaged                  35 (4.7%)     26 (6.1%)                9 (2.9%)

  Tumor size                                                        

   ≤8 cm                     268 (36.1%)   159 (37.0%)              109 (34.8%)

   \>8 cm                    304 (40.9%)   171 (39.8%)              133 (42.5%)

   Unknown                   171 (23.0%)   100 (23.2%)              71 (22.7%)

  Marital status                                                    

   Married                   434 (58.4%)   255 (59.3%)              179 (57.2%)

   Divorced                  67 (9.0%)     34 (7.9%)                33 (10.5%)

   Single                    179 (24.1%)   117 (27.2%)              62 (19.8%)

   Widowed                   63 (8.5%)     24 (5.6%)                39 (12.5%)

  Socioeconomic status                                              

   Low-SES                   380 (51.1%)   237 (55.1%)              143 (45.7%)

   High-SES                  363 (48.9%)   193 (44.9%)              170 (54.3%)

  Surgery                                                           

   Performed                 654 (88.0%)   381 (88.6%)              273 (87.2%)

   Not performed             89 (12.0%)    49 (11.4%)               40 (12.8%)

  Radiotherapy                                                      

   Performed                 212 (28.5%)   124 (28.8%)              88 (28.1%)

   Not performed             531 (71.5%)   306 (71.2%)              225 (71.9%)

  Treatment                                                         

   Both                      172 (23.1%)   99 (23.0%)               73 (23.3%)

   Surgery only              482 (64.8%)   282 (65.6%)              200 (63.9%)

   Radiotherapy only         40 (5.4%)     25 (5.8%)                15 (4.8%)

   None                      49 (6.7%)     24 (5.6%)                25 (8.0%)
  -------------------------------------------------------------------------------------

SEER -- Surveillance, Epidemiology, and End Results; NOS -- not otherwise specified; SES -- socioeconomic status.

###### 

Overall and cancer-specific survival analysis for patients with high-grade chondrosarcoma in the SEER database.

  Variable                 Univariate analysis (log-rank test)   Multivariate analysis (Cox regression)   Univariate analysis (log-rank test)   Multivariate analysis (Cox regression)                                         
  ------------------------ ------------------------------------- ---------------------------------------- ------------------------------------- ---------------------------------------- ------- --------- ------------------- ---------
  Age at diagnosis                                               \<0.001                                                                                                                         \<0.001                       
   \<60                    54.5%                                                                          Reference                                                                      57.1%             Reference           
   ≥60                     33.7%                                                                          1.85 (1.50--2.30)                     \<0.001                                  40.9%             1.54 (1.22--1.94)   \<0.001
  Race                                                           0.401                                                                                                                           0.675                         
   White                   45.0%                                                                                                                                                         50.3%                                 
   Black                   46.5%                                                                                                                                                         51.3%                                 
   Other                   51.5%                                                                                                                                                         53.6%                                 
  Sex                                                            0.135                                                                                                                           0.198                         
   Male                    43.1%                                                                                                                                                         48.5%                                 
   Female                  48.8%                                                                                                                                                         52.5%                                 
  Tumor location                                                 0.004                                                                                                                           0.001                         
   Axial                   40.5%                                                                          Reference                                                                      45.2%             Reference           
   Extremities             42.0%                                                                          0.99 (0.79--1.25)                     0.952                                    46.5%             0.98 (0.77--1.27)   0.909
   Other                   55.2%                                                                          0.95 (0.71--1.28)                     0.747                                    63.0%             0.88 (0.63--1.22)   0.438
  Pathological grade                                             \<0.001                                                                                                                         \<0.001                       
   Poorly differentiated   54.2%                                                                          Reference                                                                      60.1%             Reference           
   Undifferentiated        33.1%                                                                          1.40 (1.14--1.72)                     0.001                                    37.1%             1.38 (1.10--1.73)   0.005
  Histo-type                                                     \<0.001                                                                                                                         \<0.001                       
   Chondrosarcoma, NOS     46.3%                                                                          Reference                                                                      52.5%             Reference           
   Myxoid                  49.2%                                                                          0.97 (0.70--1.34)                     0.855                                    54.1%             0.93 (0.65--1.35)   0.718
   Mesenchymal             57.9%                                                                          0.68 (0.45--1.03)                     0.070                                    61.6%             0.70 (0.45--1.11)   0.127
   Dedifferentiated        27.3%                                                                          1.33 (1.02--1.72)                     0.032                                    30.4%             1.46 (1.10--1.92)   0.007
   Other                   63.5%                                                                          0.85 (0.31--2.33)                     0.758                                    70.4%             0.74 (0.23--2.35)   0.611
  SEER stage                                                     \<0.001                                                                                                                         \<0.001                       
   Localized               60.7%                                                                          Reference                                                                      67.8%             Reference           
   Regional                47.3%                                                                          1.45 (1.13--1.87)                     0.003                                    52.3%             1.68 (1.25--2.24)   0.001
   Distant                 14.9%                                                                          3.12 (2.34--4.15)                     \<0.001                                  16.3%             3.95 (2.87--5.43)   \<0.001
   Unstaged                56.1%                                                                          0.97 (0.57--1.65)                     0.921                                    69.8%             0.91 (0.47--1.77)   0.783
  Tumor size                                                     \<0.001                                                                                                                         \<0.001                       
   ≤8 cm                   59.6%                                                                          Reference                                                                      64.3%             Reference           
   \>8 cm                  36.5%                                                                          1.42 (1.11--1.81)                     0.006                                    42.0%             1.45 (1.11--1.90)   0.007
   Unknown                 36.7%                                                                          1.37 (1.03--1.83)                     0.030                                    42.2%             1.38 (1.00--1.90)   0.049
  Marital status                                                 \<0.001                                                                                                                         \<0.001                       
   Married                 46.4%                                                                          Reference                                                                      50.9%             Reference           
   Divorced                40.3%                                                                          1.17 (0.83--1.65)                     0.358                                    47.5%             1.12 (0.77--1.64)   0.551
   Single                  51.2%                                                                          1.02 (0.79--1.32)                     0.889                                    57.6%             0.95 (0.72--1.26)   0.727
   Widowed                 19.5%                                                                          1.42 (1.04--1.93)                     0.028                                    25.7%             1.39 (0.99--1.97)   0.059
  Socioeconomic status                                           0.025                                                                                                                           0.112                         
   Low-SES                 41.9%                                                                          Reference                                                                      47.7%                                 
   High-SES                49.6%                                                                          0.90 (0.74--1.09)                     0.273                                    54.3%                                 
  Surgery                                                        \<0.001                                                                                                                         \<0.001                       
   Performed               49.8%                                                                          Reference                                                                      54.9%             Reference           
   Not performed           13.9%                                                                          2.00 (1.51--2.66)                     \<0.001                                  17.6%             2.06 (1.53--2.78)   \<0.001
  Radiotherapy                                                   0.928                                                                                                                           0.573                         
   Performed               44.9%                                                                                                                                                         51.4%                                 
   Not performed           45.7%                                                                                                                                                         50.1%                                 
  Treatment                                                      \<0.001                                  NA                                                                                     \<0.001   NA                  
   Both                    54.3%                                                                                                                                                         59.8%                                 
   Surgery only            47.6%                                                                                                                                                         52.5%                                 
   Radiotherapy only       7.2%                                                                                                                                                          11.5%                                 
   None                    18.8%                                                                                                                                                         21.1%                                 

SEER -- Surveillance, Epidemiology, and End Results; OS -- overall survival; CSS -- cancer-specific survival; HR -- hazard ratio; CI -- confidence interval; NOS -- not otherwise specified; SES -- socioeconomic status; NA -- the analysis is not available because of the covariance.

###### 

Overall and cancer-specific survival analysis for patients with poorly differentiated chondrosarcoma in the SEER database.

  Variable                   Univariate analysis (log-rank test)   Multivariate analysis (Cox regression)   Univariate analysis (log-rank test)   Multivariate analysis (Cox regression)                                         
  -------------------------- ------------------------------------- ---------------------------------------- ------------------------------------- ---------------------------------------- ------- --------- ------------------- ---------
  Age (years) at diagnosis                                         \<0.001                                                                                                                         0.001                         
   \<60                      61.3%                                                                          Reference                                                                      64.9%             Reference           
   ≥60                       42.4%                                                                          1.59 (1.16--2.18)                     0.004                                    51.3%             1.50 (1.07--2.09)   0.018
  Race                                                             0.911                                                                                                                           0.775                         
   White                     54.8%                                                                                                                                                         60.8%                                 
   Black                     48.7%                                                                                                                                                         57.9%                                 
   Other                     51.8%                                                                                                                                                         51.8%                                 
  Sex                                                              0.381                                                                                                                           0.269                         
   Male                      52.9%                                                                                                                                                         58.4%                                 
   Female                    56.1%                                                                                                                                                         61.3%                                 
  Tumor location                                                   0.079                                                                                                                           0.032                         
   Axial                     46.0%                                                                                                                                                         51.8%             Reference           
   Extremities               54.1%                                                                                                                                                         58.5%             0.81 (0.57--1.15)   0.242
   Other                     62.8%                                                                                                                                                         70.9%             0.89 (0.57--1.40)   0.611
  Histo-type                                                       \<0.001                                                                                                                         \<0.001                       
   Chondrosarcoma, NOS       53.8%                                                                          Reference                                                                      60.2%             Reference           
   Myxoid                    57.9%                                                                          0.99 (0.64--1.54)                     0.953                                    65.8%             0.92 (0.54--1.57)   0.749
   Mesenchymal               60.4%                                                                          1.27 (0.71--2.25)                     0.423                                    63.1%             1.35 (0.71--2.56)   0.357
   Dedifferentiated          25.1%                                                                          1.84 (1.22--2.75)                     0.003                                    35.9%             2.00 (1.30--3.08)   0.002
   Other                     71.4%                                                                          0.64 (0.16--2.67)                     0.546                                    85.7%             0.39 (0.05--2.88)   0.358
  SEER stage                                                       \<0.001                                                                                                                         \<0.001                       
   Localized                 66.2%                                                                          Reference                                                                      75.2%             Reference           
   Regional                  54.4%                                                                          1.36 (0.97--1.91)                     0.082                                    58.9%             1.84 (1.22--2.78)   0.004
   Distant                   18.8%                                                                          3.01 (1.97--4.60)                     \<0.001                                  21.8%             4.48 (2.79--7.21)   \<0.001
   Unstaged                  62.9%                                                                          0.78 (0.41--1.51)                     0.461                                    78.5%             0.76 (0.32--1.78)   0.525
  Tumor size                                                       \<0.001                                                                                                                         \<0.001                       
   ≤8 cm                     68.8%                                                                          Reference                                                                      74.4%             Reference           
   \>8 cm                    46.4%                                                                          1.49 (1.06--2.08)                     0.021                                    52.8%             1.72 (1.16--2.54)   0.007
   Unknown                   41.7%                                                                          1.69 (1.12--2.54)                     0.012                                    47.7%             1.89 (1.20--2.97)   0.006
  Marital status                                                   0.034                                                                                                                           0.609                         
   Married                   53.3%                                                                          Reference                                                                      58.5%                                 
   Divorced                  49.1%                                                                          0.91 (0.55--1.53)                     0.849                                    60.9%                                 
   Single                    56.7%                                                                          0.84 (0.59--1.21)                     0.333                                    62.4%                                 
   Widowed                   32.1%                                                                          1.30 (0.79--2.15)                     0.299                                    43.4%                                 
  Socioeconomic status                                             0.024                                                                                                                           0.588                         
   Low-SES                   49.1%                                                                          Reference                                                                      56.6%                                 
   High-SES                  59.8%                                                                          0.76 (0.57--1.01)                     0.062                                    63.6%                                 
  Surgery                                                          \<0.001                                                                                                                         \<0.001                       
   Performed                 59.1%                                                                          Reference                                                                      64.7%             Reference           
   Not performed             17.3%                                                                          2.58 (1.72--3.88)                     \<0.001                                  23.3%             2.35 (1.55--3.56)   \<0.001
  Radiotherapy                                                     0.055                                                                                                                           0.086                         
   Performed                 48.5%                                                                                                                                                         56.2%                                 
   Not performed             56.6%                                                                                                                                                         61.6%                                 
  Treatment                                                        \<0.001                                  NA                                                                                     \<0.001   NA                  
   Both                      60.2%                                                                                                                                                         66.3%                                 
   Surgery only              58.8%                                                                                                                                                         64.1%                                 
   Radiotherapy only         4.4%                                                                                                                                                          10.6%                                 
   None                      22.2%                                                                                                                                                         23.4%                                 

SEER -- Surveillance, Epidemiology, and End Results; OS -- overall survival; CSS -- cancer-specific survival; HR -- hazard ratio; CI -- confidence interval; NOS -- not otherwise specified; SES -- socioeconomic status; NA -- the analysis is not available because of the covariance.

###### 

Overall and cancer-specific survival analysis for patients with undifferentiated chondrosarcoma in the SEER database.

  Variable                   Univariate analysis (log-rank test)   Multivariate analysis (Cox regression)   Univariate analysis (log-rank test)   Multivariate analysis (Cox regression)                                          
  -------------------------- ------------------------------------- ---------------------------------------- ------------------------------------- ---------------------------------------- -------- --------- ------------------- ---------
  Age (years) at diagnosis                                         \<0.001                                                                                                                          \<0.001                       
   \<60                      43.4%                                                                          Reference                                                                      44.6%              Reference           
   ≥60                       21.6%                                                                          2.16 (1.58--2.97)                     \<0.001                                  28.3%              1.75 (1.25--2.45)   0.001
  Race                                                             0.037                                                                                                                            0.089                         
   White                     30.6%                                                                          Reference                                                                      34.8%                                  
   Black                     43.3%                                                                          0.80 (0.43--1.49)                     0.485                                    43.3%                                  
   Other                     50.6%                                                                          0.44 (0.23--0.84)                     0.012                                    54.8%                                  
  Sex                                                              0.098                                                                                                                            0.321                         
   Male                      28.3%                                                                                                                                                         33.1%                                  
   Female                    38.7%                                                                                                                                                         41.3%                                  
  Tumor location                                                   0.003                                                                                                                            0.001                         
   Axial                     31.6%                                                                          Reference                                                                      35.0%              Reference           
   Extremities               25.7%                                                                          1.14 (0.80--1.62)                     0.474                                    29.9%              1.13 (0.77--1.64)   0.543
   Other                     45.6%                                                                          1.08 (0.67--1.73)                     0.763                                    51.5%              0.89 (0.53--1.51)   0.679
  Histo-type                                                       0.007                                                                                                                            0.008                         
   Chondrosarcoma, NOS       29.5%                                                                          Reference                                                                      36.2%              Reference           
   Myxoid                    37.5%                                                                          1.03 (0.63--1.67)                     0.912                                    39.5%              1.11 (0.65--1.88)   0.712
   Mesenchymal               55.5%                                                                          0.52 (0.29--0.92)                     0.026                                    60.3%              0.52 (0.27--1.01)   0.053
   Dedifferentiated          24.0%                                                                          1.07 (0.77--1.50)                     0.681                                    27.8%              1.08 (0.75--1.55)   0.680
   Other                     NA^\*^                                                                         1.41 (0.33--6.05)                     0.647                                    NA^\*^             1.61 (0.37--7.02)   0.527
  SEER stage                                                       \<0.001                                                                                                                          \<0.001                       
   Regional                  37.2%                                                                          1.66 (1.13--2.43)                     0.010                                    41.8%              1.54 (1.00--2.36)   0.048
   Distant                   11.6%                                                                          3.41 (2.25--5.16)                     \<0.001                                  12.1%              3.66 (2.35--5.72)   \<0.001
   Unstaged                  33.3%                                                                          1.23 (0.42--3.59)                     0.711                                    38.9%              1.18 (0.35--3.99)   0.791
  Tumor size                                                       0.001                                                                                                                            0.001                         
   ≤8 cm                     46.0%                                                                          Reference                                                                      50.8%              Reference           
   \>8 cm                    23.2%                                                                          1.29 (0.89--1.86)                     0.179                                    26.8%              1.28 (0.87--1.89)   0.219
   Unknown                   29.9%                                                                          1.17 (0.76--1.79)                     0.471                                    34.6%              0.96 (0.59--1.54)   0.850
  Marital status                                                   0.001                                                                                                                            0.001                         
   Married                   35.8%                                                                          Reference                                                                      39.3%              Reference           
   Divorced                  32.1%                                                                          1.17 (0.71--1.91)                     0.538                                    33.1%              1.21 (0.72--2.03)   0.465
   Single                    38.3%                                                                          1.12 (0.74--1.68)                     0.591                                    48.0%              0.98 (0.62--1.54)   0.922
   Widowed                   10.7%                                                                          1.54 (1.01--2.34)                     0.045                                    13.1%              1.65 (1.06--2.57)   0.027
  Socioeconomic status                                             0.559                                                                                                                            0.584                         
   Low-SES                   31.8%                                                                                                                                                         35.2%                                  
   High-SES                  35.0%                                                                                                                                                         39.6%                                  
  Surgery                                                          0.003                                                                                                                            0.001                         
   Performed                 36.1%                                                                          Reference                                                                      40.9%              Reference           
   Not performed             10.8%                                                                          1.84 (1.17--2.89)                     0.008                                    12.4%              1.90 (1.19--3.04)   0.008
  Radiotherapy                                                     0.015                                                                                                                            0.004                         
   Performed                 41.1%                                                                          Reference                                                                      46.2%              Reference           
   Not performed             30.0%                                                                          1.57 (1.09--2.27)                     0.017                                    33.4%              1.66 (1.11--2.50)   0.016
  Treatment                                                        \<0.001                                  NA^\#^                                                                                  \<0.001   NA^\#^              
   Both                      46.3%                                                                                                                                                         52.8%                                  
   Surgery only              32.3%                                                                                                                                                         36.5%                                  
   Radiotherapy only         12.5%                                                                                                                                                         12.5%                                  
   None                      8.3%                                                                                                                                                          10.9%                                  

SEER -- Surveillance, Epidemiology, and End Results; OS -- overall survival; CSS -- cancer-specific survival; HR -- hazard ratio; CI -- confidence interval; NOS -- not otherwise specified; SES -- socioeconomic status;

NA^\*^ -- the analysis is not available because of the small sample size;

NA^\#^ -- the analysis is not available because of the covariance.

###### 

Subgroup survival analysis for patients with different histo-types of undifferentiated chondrosarcoma in the SEER database.

  Histo-type             Variable       Univariate analysis (log-rank test)   Multivariate analysis (Cox regression)   Univariate analysis (log-rank test)   Multivariate analysis (Cox regression)                                       
  ---------------------- -------------- ------------------------------------- ---------------------------------------- ------------------------------------- ---------------------------------------- ------- ------------------- ------- --
  Chondrosarco-ma, NOS   Radiotherapy                                         0.642                                                                                                                           0.709                       
   Performed             27.8%                                                                                                                               32.0%                                                                        
   Not performed         31.0%                                                                                                                               37.1%                                                                        
  Treatment                             0.064                                                                                                                                                         0.085                               
   Both                  27.9%                                                                                                                               40.8%                                                                        
   Surgery only          34.9%                                                                                                                               39.1%                                                                        
   Radiotherapy only     1.0%                                                                                                                                1.4%                                                                         
   None                  8.0%                                                                                                                                11.5%                                                                        
  Myxoid                 Radiotherapy                                         0.608                                                                                                                           0.211                       
   Performed             42.7%                                                                                                                               52.9%                                                                        
   Not performed         28.6%                                                                                                                               28.6%                                                                        
  Treatment                             0.000                                                                                                                                                         0.000                               
   Both                  45.6%                                                                                                                               58.0%                                                                        
   Surgery only          30.8%                                                                                                                               30.8%                                                                        
   Radiotherapy only     NA^\*^                                                                                                                              NA^\*^                                                                       
   None                  NA^\*^                                                                                                                              NA^\*^                                                                       
  Mesenchymal            Radiotherapy                                         0.934                                                                                                                           0.883                       
   Performed             53.7%                                                                                                                               59.7%                                                                        
   Not performed         56.7%                                                                                                                               60.2%                                                                        
  Treatment                             0.703                                                                                                                                                         0.380                               
   Both                  60.9%                                                                                                                               69.6%                                                                        
   Surgery only          61.4%                                                                                                                               65.1%                                                                        
   Radiotherapy only     1.0%                                                                                                                                1.0%                                                                         
   None                  33.3%                                                                                                                               33.3%                                                                        
  Dedifferentiated       Radiotherapy                                         0.020                                                                                                                           0.005                       
   Performed             50.2%                                                Reference                                                                      58.3%                                            Reference                   
   Not performed         20.6%                                                2.64 (1.17--5.95)                        0.019                                 21.5%                                            3.56 (1.39--9.15)   0.008   
  Treatment                             0.015                                 NA^\#^                                                                                                                  0.007   NA^\#^                      
   Both                  53.3%                                                                                                                               61.9%                                                                        
   Surgery only          23.6%                                                                                                                               24.3%                                                                        
   Radiotherapy only     NA^\*^                                                                                                                              NA^\*^                                                                       
   None                  NA^\*^                                                                                                                              NA^\*^                                                                       

SEER -- Surveillance, Epidemiology, and End Results; OS -- overall survival; CSS -- cancer-specific survival; HR -- hazard ratio; CI -- confidence interval; NOS -- not otherwise specified;

NA^\*^ -- the analysis is not available because of the small sample size;

NA^\#^ -- the analysis is not available because of the covariance.
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